Albumin fusion proteins

• US 8,143,026 B2
• Filed: 08/03/2009
• Issued: 03/27/2012
• Est. Priority Date: 02/09/2004
• Status: Active Grant

• Current Assignee: Human Genome Sciences Incorporated (GlaxoSmithKline PLC)
• Original Assignee: Human Genome Sciences Incorporated (GlaxoSmithKline PLC)
• Inventors: Rosen, Craig A., Haseltine, William A., Ruben, Steven M., Moore, Paul A., Bock, Jason B., LaFleur, David
• Primary Examiner(s): Rao, Manjunath
• Assistant Examiner(s): Moore, William W
• Application Number:
  US12/534,585
• Publication Number:
  US 20100093627A1
• Time in Patent Office: 967 Days
• Field of Search: None
• US Class Current: 435/69.7
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/00 Drugs for disorders of the endocrine system
• CPC Class Codes: C07K 14/765 Serum albumin, e.g. HSA
• CPC Class Codes: C07K 2319/31 fusions, other than Fc, for prolonged plasma life, e.g. albumin
• CPC Class Codes: C07K 2319/35 containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
• CPC Class Codes: C12N 15/62 DNA sequences coding for fusion proteins

Abstract

The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disorders or conditions using albumin fusion proteins of the invention.

Claims

1. An albumin fusion protein expressed from a host cell containing a GLP-1-albumin fusion protein expression construct comprising a polynucleotide encoding said fusion protein amino acid sequence selected from the group consisting of:

(a) SEQ ID NO;

319, and

(b) SEQ ID NO;

322.

2. An isolated host cell comprising a polynucleotide encoding the amino acid sequence set forth in SEQ ID NO:

319.

3. The host cell of claim 2, wherein said host cell is a yeast cell or a mammalian cell.

4. The host cell of claim 3, wherein said yeast cell is Saccharomyces cerevisiae.

5. The host cell of claim 3, wherein said mammalian cell is a Chinese hamster ovary (CHO) cell or a NS0 myeloma cell.